
## SCARD Pool report for 01-01-2017 to 31-12-2017

| | | | |
|---|---|---|---|
| **Participants** | Doctors | 426 | |
| | Patients | 61,392 | |
| **Specimens** | New lesions | 113,385 | 84.49% |
| | Previously biopsied lesions | 20,819 | 15.51% |
| | Total lesions | 134,204 | 100.00% |

**Breakdown of new versus previously biopsied specimens**




| | |
|---|---|
| Percentage of new lesions tested which were malignant | 61.68% |
| Percentage of Definitively excised lesions that were malignant | 79.48% |
| Lesions tested to find one melanoma (NNT) | 4.46 |
| Percentage of lesions tested for NMSC which were NMSC | 75.95% |
| Ratio of New BCCs : New Melanomas | 10:1 |

## Accuracy

### Diagnostic sensitivity

| | |
|---|---|
| Melanomas | 71.83% of 3,678 |
| All NMSC | 95.56% of 64,706 |
| BCCs | 91.37% of 35,199 |
| SCCs | 81.46% of 29,106 |

### Positive predictive value

| | |
|---|---|
| Melanomas | 43.23% of 6,112 |
| All NMSC | 81.53% of 75,843 |
| BCCs | 42.41% of 75,843 |
| SCCs | 63.53% of 37,319 |

## Adequacy

### Percentage of definitively managed malignant cases where surgical margins were adequate


| | |
|---|---|
| BCC | 85.82% of 24,276 |
| IEC/Bowens disease | 82.08% of 7,188 |
| SCC | 87.33% of 8,895 |
| Keratoacanthoma | 92.86% of 1,078 |
| Melanoma - in situ | 73.19% of 2,577 |
| Melanoma - invasive | 72.13% of 635 |
| Melanoma - invasive > 1mm | 36.96% of 92 |
| Other malignant | 63.11% of 103 |


© 2026 SCARD Systems Pty Ltd

## Lesion Breakdown

### Histological Diagnosis

| | | |
|---|---|---|
| BCC (unspecified type) | 2 | 0.00% |
| BCC - Superficial | 11,278 | 9.93% |
| BCC - Nodular/Solid | 18,373 | 16.17% |
| BCC - Aggressive | 5,546 | 4.88% |
| IEC/Bowens disease | 15,299 | 13.47% |
| SCC | 12,241 | 10.77% |
| Keratoacanthoma | 1,566 | 1.38% |
| Pinkus Fibroepithelioma | 15 | 0.01% |
| Merkel cell tumour | 8 | 0.01% |
| Other malignant | 163 | 0.14% |
| NMSC Metastasis | 3 | 0.00% |
| Melanoma - in situ | 2,709 | 2.38% |
| Melanoma - invasive | 754 | 0.66% |
| Melanoma - invasive > 1mm | 189 | 0.17% |
| Melanoma - metastasis | 26 | 0.02% |
| MELTUMP | 212 | 0.19% |
| Naevus - other | 6,466 | 5.69% |
| Naevus - dysplastic/Clark | 3,839 | 3.38% |
| Naevus - blue | 416 | 0.37% |
| Naevus - Spitz/Reed | 119 | 0.10% |
| Naevus - Compound | 6 | 0.01% |
| Solar keratosis | 11,079 | 9.75% |
| Solar lentigo | 1,480 | 1.30% |
| Seborrhoeic keratosis | 5,696 | 5.01% |
| Lentigo Simplex | 1 | 0.00% |
| Lichenoid keratosis (LPLK) | 2,337 | 2.06% |
| Dermatofibroma | 847 | 0.75% |
| Sebaceous gland hyperplasia | 256 | 0.23% |
| Benign cyst | 1,783 | 1.57% |
| Other benign | 7,793 | 6.86% |
| Histology Pending | 233 | 0.21% |





© 2026 SCARD Systems Pty Ltd

## Procedures

**Definitive Surgical Management used to exclude melanoma**

| | | |
|---|---|---|
| Ellipse | 2,906 | 80.32% |
| Flap | 80 | 2.21% |
| Graft - SSG | 4 | 0.11% |
| Graft - FTSG | 10 | 0.28% |
| No Closure | 7 | 0.19% |
| Shave/Saucerisation | 141 | 3.90% |
| Curettage & Cautery | 15 | 0.41% |
| Liquid N2 freeze/thaw | 0 | 0% |
| PDT | 0 | 0% |
| Imiquimod | 1 | 0.03% |
| 5 FU cream | 1 | 0.03% |
| GP referral | 299 | 8.26% |
| Specialist referral | 62 | 1.71% |
| Other | 86 | 2.38% |

**Biopsy used to exclude melanoma**

| | | |
|---|---|---|
| Punch - sample | 822 | 6.24% |
| Shave - sample | 1,599 | 12.14% |
| Incisional | 168 | 1.28% |
| Punch - removal | 2,703 | 20.51% |
| Shave - removal | 3,431 | 26.04% |
| Excisional | 4,435 | 33.66% |
| Curettage | 9 | 0.07% |
| Other | 8 | 0.06% |

**Breakdown of definitive management procedures for malignant conditions**

| | | |
|---|---|---|
| Ellipse | 38,636 | 63.69% |
| Flap | 5,380 | 8.87% |
| Graft - SSG | 329 | 0.54% |
| Graft - FTSG | 1,288 | 2.12% |
| No Closure | 365 | 0.60% |
| Shave/Saucerisation | 1,176 | 1.94% |
| Curettage & Cautery | 6,304 | 10.39% |
| Liquid N2 freeze/thaw | 863 | 1.42% |
| PDT | 148 | 0.24% |
| Imiquimod | 625 | 1.03% |
| 5 FU cream | 1,279 | 2.11% |
| GP referral | 1,905 | 3.14% |
| Specialist referral | 1,543 | 2.54% |
| Other | 291 | 0.48% |

**Breakdown of definitive management procedures for benign conditions**

| | | |
|---|---|---|
| Ellipse | 5,553 | 73.19% |
| Flap | 102 | 1.34% |
| Graft - SSG | 3 | 0.04% |
| Graft - FTSG | 14 | 0.18% |
| No Closure | 20 | 0.26% |
| Shave/Saucerisation | 604 | 7.96% |
| Liquid N2 freeze/thaw | 199 | 2.62% |
| 5 FU cream | 68 | 0.90% |
| GP referral | 243 | 3.20% |
| Specialist referral | 51 | 0.67% |
| Other | 202 | 2.66% |


© 2026 SCARD Systems Pty Ltd

## Procedures (continued)


**Percentage of procedures/closures that were complex**

| | |
|---|---|
| Complex Closures | 1.26% of 9,449 |
| Complex Closures (inc Curettage & Cautery) | 1.20% of 9,941 |

## Locations

**Breakdown of melanomas by location and percentage melanomas of total lesions at that location**

| | | |
|---|---|---|
| Nose | 44 | 0.65% of 6,773 |
| Lip | 5 | 0.28% of 1,771 |
| Ear | 80 | 1.70% of 4,707 |
| Eyelid | 9 | 0.82% of 1,097 |
| Other face | 367 | 1.90% of 19,292 |
| Scalp | 88 | 2.16% of 4,067 |
| Neck | 127 | 2.22% of 5,720 |
| Shoulder | 271 | 4.86% of 5,578 |
| Chest | 190 | 2.75% of 6,920 |
| Abdomen | 85 | 6.04% of 1,407 |
| Genitalia | 4 | 2.61% of 153 |
| Back | 1200 | 7.38% of 16,251 |
| Buttock | 9 | 3.56% of 253 |
| Arm | 397 | 5.82% of 6,826 |
| Forearm | 226 | 2.62% of 8,633 |
| Hand Dorsal | 10 | 0.23% of 4,353 |
| Hand Palmar | 2 | 4.76% of 42 |
| Finger Dorsal | 4 | 0.52% of 775 |
| Finger Nail | 0 | 0% of 16 |
| Finger Palmar | 0 | 0% of 20 |
| Thigh | 181 | 5.26% of 3,439 |
| Leg | 353 | 2.52% of 14,030 |
| Foot Dorsal | 15 | 1.58% of 950 |
| Foot Plantar | 8 | 6.15% of 130 |
| Toe Dorsal | 1 | 0.75% of 134 |
| Toe Nail | 1 | 4.00% of 25 |
| Toe Plantar | 1 | 4.35% of 23 |
| Palm Or Sole | 0 | 0% of 0 |






© 2026 SCARD Systems Pty Ltd